A STUDY OF CLINIC EQUIVALENCE OF TWO DRUG FORMS OF ENALAPRIL IN PATIENTS WITH ARTERIAL HYPERTENSION

• Main Authors: N. P. Kutishenko, S. Yu. Martsevich, S. A. Shalnova, A. D. Deyev, V. V. Yakusevich
• Format: Article
• Language: Russian
• Published: «FIRMA «SILICEA» LLC 2003-10-01
• Series: Российский кардиологический журнал
• Subjects: arterial hypertension; cost of therapy; enalapril drug forms (renitec® and enam®)
• Online Access: https://russjcardiol.elpub.ru/jour/article/view/1797
• ISSN: 1560-4071; 2618-7620

In a randomized open crossover study clinic equivalence of two drug forms of enalapril (Renitec®and Епат® in patients with arterial hypertension (AH) was compared. 46 patients with mild to moderate AH (mean age 57, 0 ± 12, 5years) have been studied. All underwent courses of treatment with Renitec® and Enam® 4 weeks each. Every drug's initial daily dose was 10 mg and increased to 20 mg daily in case of insufficient antihypertensive effect. The effect of treatment was evaluated by daily BP dynamics. After 4 weeks therapy Enam® and Renitec® resulted in reliable indices reduction both systolic BP (SBP) and diastolic BP (DBP). At the end of a course of treatment with Enam® SBP decreased to 16, 8 mm Hg, DBP to 8, 2 mm Hg (in both cases p < 0,001). Under the influence of Renitec® SBP decreased to 19, 1 mm Hg, DBP to 9, 6 mm Hg (in both cases the tendency to more marked effect of Renitec® was noted, but differences between two medications were not statistically significant. During the course of both medications insignificant inauthentic increase of HR was observed. The dose-effect analysis showed that for achieving the equal level of SBP reduction the dose of Enam® should be slightly higher, at the same time the cost of therapy with much as Renitec® BP reduction was less in treatmentwith Enam®, then with Renitec®. Two drugforms of enalapril Enam® and Renitec® are clinically equivalent, at the same time the daily therapy of AH in treatment with Enam® prove to be significantly inexpensive.